Medpace Holdings, Inc. $MEDP Shares Sold by Caerus Investment Advisors LLC

Caerus Investment Advisors LLC reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 66.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 774 shares of the company’s stock after selling 1,523 shares during the quarter. Caerus Investment Advisors LLC’s holdings in Medpace were worth $372,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. Argent Capital Management LLC increased its position in shares of Medpace by 0.3% during the first quarter. Argent Capital Management LLC now owns 76,590 shares of the company’s stock worth $36,778,000 after purchasing an additional 250 shares in the last quarter. Turtle Creek Asset Management Inc. boosted its position in shares of Medpace by 4,741.8% in the 1st quarter. Turtle Creek Asset Management Inc. now owns 135,570 shares of the company’s stock worth $65,099,000 after purchasing an additional 132,770 shares in the last quarter. NewEdge Advisors LLC grew its stake in Medpace by 29.9% during the 1st quarter. NewEdge Advisors LLC now owns 2,473 shares of the company’s stock worth $1,188,000 after buying an additional 569 shares during the last quarter. Bank of America Corp DE grew its stake in Medpace by 0.7% during the 1st quarter. Bank of America Corp DE now owns 212,183 shares of the company’s stock worth $101,888,000 after buying an additional 1,487 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in Medpace by 21.0% during the 1st quarter. Janus Henderson Group PLC now owns 124,954 shares of the company’s stock worth $60,026,000 after buying an additional 21,709 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

Shares of MEDP opened at $577.11 on Friday. The company’s fifty day moving average price is $507.61 and its 200-day moving average price is $493.77. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The firm has a market capitalization of $16.11 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 2.57 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the business posted $3.10 EPS. The firm’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insider Activity

In other news, CEO August J. Troendle sold 3,728 shares of the stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $600.85, for a total value of $2,239,968.80. Following the transaction, the chief executive officer directly owned 642,456 shares of the company’s stock, valued at approximately $386,019,687.60. This represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the transaction, the vice president owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 31,087 shares of company stock valued at $16,203,054. Company insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on MEDP. Mizuho increased their price target on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Barclays set a $600.00 price target on Medpace in a report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Finally, Robert W. Baird lifted their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.